Compare STRT & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STRT | NGEN |
|---|---|---|
| Founded | 1908 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 331.1M | 317.6M |
| IPO Year | 1996 | N/A |
| Metric | STRT | NGEN |
|---|---|---|
| Price | $90.72 | $4.14 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 34.5K | ★ 128.3K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.53 | N/A |
| EPS | ★ 3.26 | N/A |
| Revenue | ★ $439,195,000.00 | N/A |
| Revenue This Year | $4.22 | N/A |
| Revenue Next Year | $2.04 | N/A |
| P/E Ratio | $27.89 | ★ N/A |
| Revenue Growth | ★ 5.24 | N/A |
| 52 Week Low | $31.71 | $3.73 |
| 52 Week High | $92.50 | $5.93 |
| Indicator | STRT | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 59.53 | 37.03 |
| Support Level | $62.09 | $3.73 |
| Resistance Level | $92.45 | $4.50 |
| Average True Range (ATR) | 4.48 | 0.23 |
| MACD | -0.08 | 0.06 |
| Stochastic Oscillator | 85.91 | 45.45 |
Strattec Security Corp designs develops, manufactures, and markets mechanical locks, electronically enhanced locks, and keys. It also produces ignition lock housings; and access control products, including latches, power sliding door systems, and door handles. Strattec ships products to customer locations in the United States, Canada, Mexico, Europe, South America, Korea, and China, and provides full-service aftermarket support. Strattec also supplies products for the heavy truck and recreational vehicle markets, as well as precision, die castings.
NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.